Breast cancer
Management of HER2+ MBC

Inés (35 years old)

Inés is a 35-year-old woman, who stopped adjuvant treatment for early breast cancer 3 months ago. At the follow-up visit, she presents with chest pain and stage II dyspnoea, which she experiences since the last 2 months.

Assessment summary

  • Premenopausal
  • No relevant comorbidities
  • ECOG PS: 1
  • Medical history
    • 18 months ago: diagnosis of stage II early breast cancer (cT3N0M0)
    • Tumour biology (breast lesion): invasive ductal carcinoma, G3, Ki67 40%, ER 100%, PgR 10%, HER2 IHC 3+
    • Neoadjuvant sequential chemotherapy + dual HER2-blockade
    • Lumpectomy and sentinel lymph node dissection (pCR: ypT0N0)
    • Adjuvant treatment: maintenance dual blockade (trastuzumab-pertuzumab every 3 weeks for 14 cycles, stopped 3 months ago) and ongoing endocrine therapy (AI + LHRH analogue)
  • Clinical exam: suspicion of bilateral pleural effusion
  • PET-CT: bilateral pulmonary metastasis with bilateral pleural effusion without lymphangitis associated with hepatic bilobular metastasis
  • Liver biopsy: breast cancer (invasive ductal carcinoma), ER 100%, PgR 10%, HER2 IHC 3+, Ki67 25%

Which of the following treatment options would you choose for this patient?